Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Aug 26, 2014; 6(8): 855-860
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.855
Published online Aug 26, 2014. doi: 10.4330/wjc.v6.i8.855
Management of renal artery stenosis: What does the experimental evidence tell us?
Mohammed Al-Suraih, Joseph Peter Grande, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55905, United States
Author contributions: Al-Suraih M performed a literature review and prepared a rough draft of this manuscript; Grande JP was involved in editing of the manuscript and preparation of the final draft; both authors have approved the final draft of this manuscript.
Correspondence to: Joseph Peter Grande, MD, PhD, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, United States. grande.joseph@mayo.edu
Telephone: +1-507-2669356 Fax: +1-507-2661163
Received: December 31, 2013
Revised: March 4, 2014
Accepted: June 10, 2014
Published online: August 26, 2014
Processing time: 260 Days and 13 Hours
Revised: March 4, 2014
Accepted: June 10, 2014
Published online: August 26, 2014
Processing time: 260 Days and 13 Hours
Core Tip
Core tip: Renovascular hypertension is a common public health problem, particularly in older patients with underlying atherosclerotic vascular disease. Recent studies have shown that restoration of blood flow in these patients fails to improve renal function or survival. Recent studies to define basic mechanisms underlying the development of chronic renal disease in renin angiotensin system (RAS) have shown that pro-inflammatory pathways may play a critical role in this process. Therapeutic approaches that target inflammatory pathways may provide the basis for novel and more effective treatments for patients with RAS.